| 13.75 0.29 (2.15%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.41 | 1-year : | 23.84 |
| Resists | First : | 17.47 | Second : | 20.41 |
| Pivot price | 11.92  |
|||
| Supports | First : | 11.4 | Second : | 7.65 |
| MAs | MA(5) : | 13.52 |
MA(20) : | 11.29 |
| MA(100) : | 9.34 |
MA(250) : | 0 | |
| MACD | MACD : | 1.1 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 58.3 |
D(3) : | 57.8 |
| RSI | RSI(14): 64 |
|||
| 52-week | High : | 17.47 | Low : | 7.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ANL ] has closed below upper band by 15.2%. Bollinger Bands are 132.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 13.76 - 13.83 | 13.83 - 13.89 |
| Low: | 11.88 - 11.95 | 11.95 - 12.01 |
| Close: | 13.63 - 13.75 | 13.75 - 13.86 |
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.
Fri, 09 Feb 2024
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In ... - Markets Insider
Tue, 03 Oct 2023
Adlai Nortye Ltd. Announces Closing of Initial Public Offering - GlobeNewswire
Fri, 29 Sep 2023
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 37 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 6.9 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 3 (K) |
| EPS | -7.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -24.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.9 |
| PEG Ratio | 0 |
| Price to Book value | -0.57 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|